Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?
Recent studies have uncovered more and more evidence demonstrating the adverse relationship between depression and ischemic heart disease. One of the most significant mechanisms that may explain the adverse relationship is the increased platelet activity, otherwise known as aggregation, observed to occur in patients with depression or ischemic heart disease. Platelet activity is further elevated in patients with depression and ischemic heart disease. Selective serotonin reuptake inhibitors are antidepressants and also act like platelet inhibitors. The results of large-scale clinical trials suggest that the use of selective serotonin reuptake inhibitors may reduce cardiac events in post-myocardial infarction patients or in those with unstable angina that may be related to the effects of selective serotonin reuptake inhibitors on platelet aggregation.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Selective Serotonin Reuptake Inhibitors
- Psychiatry
- Platelet Aggregation
- Myocardial Ischemia
- Myocardial Infarction
- Humans
- Drug Prescriptions
- Depression
- Clinical Trials as Topic
- Antidepressive Agents, Second-Generation
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Selective Serotonin Reuptake Inhibitors
- Psychiatry
- Platelet Aggregation
- Myocardial Ischemia
- Myocardial Infarction
- Humans
- Drug Prescriptions
- Depression
- Clinical Trials as Topic
- Antidepressive Agents, Second-Generation